	US 12,297,450 B2
	CRISPR-Cas13 system and use thereof
Junbin Liang, Guangdong (CN); Xingxiang Liang, Guangdong (CN); Yang Sun, Zhejiang (CN); Hui Xu, Guangdong (CN); Kaiwei Si, Guangdong (CN); Qiuting Li, Guangdong (CN); Zhiqin Peng, Guangdong (CN); and Desheng Huangfu, Guangdong (CN)
Assigned to GUANGZHOU REFORGENE MEDICINE CO., LTD., Guangzhou (CN); and ZHEJIANG SYNSORBIO TECHNOLOGY CO., LTD, Shaoxing (CN)
Filed by GUANGZHOU REFORGENE MEDICINE CO., LTD., Guangdong (CN); and ZHEJIANG SYNSORBIO TECHNOLOGY CO., LTD, Zhejiang (CN)
Filed on Jun. 27, 2024, as Appl. No. 18/755,750.
Application 18/755,750 is a continuation of application No. PCT/CN2023/115093, filed on Aug. 25, 2023.
Claims priority of application No. 202211035342.8 (CN), filed on Aug. 26, 2022; and application No. 202310457880.4 (CN), filed on Apr. 24, 2023.
Prior Publication US 2024/0392323 A1, Nov. 28, 2024
Int. Cl. C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01)

CPC C12N 15/907 (2013.01) [C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 2310/20 (2017.05); C12N 2310/531 (2013.01)]

27 Claims

1. A non-naturally occurring Cas13 protein, wherein the amino acid sequence of the Cas13 protein has at least 90% sequence identity compared to SEQ ID NO: 1, and comprises one or more mutations compared to SEQ ID NO: 1.